Search

everythinglearnresearchcommunity

for

Search:↓

The update highlights that non-classic congenital adrenal hyperplasia is common in women with excess male hormones, requires specific hormone tests for diagnosis, and has various treatment options depending on age and symptoms.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.

Finasteride effectively treats BPH but may increase sexual dysfunction risk.

Flutamide rarely causes liver toxicity in prostate cancer patients.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.

Certain natural compounds called terpenes may help prevent prostate cancer.

Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.

Shorter PSADT after prostate surgery is linked to higher risk of death.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

Liquorice may reduce testosterone and affect male reproductive organs, potentially helping treat conditions like prostate cancer.

Created microspheres show potential for safe and effective use in prostate artery embolization.

Researchers found four natural compounds that can change DHT levels in prostate cancer cells.

CT scans can find serious prostate cancer even when PSA levels are low.

The compound was successfully made and shows potential for treating prostate cancer.

Finasteride treats hair loss and reduces prostate cancer risk.

Finasteride may reduce prostate bleeding by lowering blood vessel growth factor levels and blood vessel density in certain prostate areas.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Using finasteride with TIP extends time off period for prostate cancer patients.

Men who start losing hair at age 30 may have a lower risk of prostate cancer.

Finasteride affects prostate weights and pituitary activity differently with age.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.

Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.

5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.